89bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

89bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

89bio, Inc. reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 87.40% for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2025-08-08

• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-03-31 was 87.20%, a 3.54% decline year-over-year.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2024-03-31 was 90.40%, a 3.00% decline year-over-year.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-03-31 was 93.20%, a 2.42% increase year-over-year.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2022-03-31 was 91.00%, a 6.76% decline year-over-year.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 91.50%, a 7.76% decline from fiscal 2023.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 99.20%, a 9.01% increase from fiscal 2022.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 91.00%, a 0.98% decline from fiscal 2021.
• 89bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 91.90%, a 5.84% decline from fiscal 2020.